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Abstract
p300/CBP–associated factor (PCAF ) is a coactivator
of the tumor suppressor, p53. PCAF participates in
p53’s transactivation of target genes through acetyla-
tion of both bound p53 and histones within p53 target
promoters. Using microarrays, we discovered that
PCAF itself is induced by p53 in a panel of breast
tumor cell lines. Two p53 mutant breast tumor cell
lines, BT-549 and UACC-1179, were chosen for further
study of PCAF induction by wild-type p53. PCAF in-
duction following adenoviral transduction of p53 ex-
pression was confirmed with real-time polymerase
chain reaction in a time course experiment. Chromatin
immunoprecipitation experiments then showed that
PCAF induction was associated with increased p53
binding to the PCAF promoter, which contains p53
consensus-binding sites. PCAF induction by p53 ac-
tivity was further demonstrated in wild-type p53
MCF10A cells when PCAF expression was induced
following activation of endogenous wild-type p53 with
doxorubicin in a dose- and time-dependent manner.
Furthermore, the doxorubicin-induced increase in
PCAF expression was blocked by pretreatment of the
MCF10A cells with siRNA (small interfering RNA)
targeted against p53 mRNA. Taken together, the
results show that PCAF expression can be induced
by wild-type p53.
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Introduction
The tumor suppressor, p53, functions primarily through
transcriptional transactivation of its target genes to block
proliferation of damaged cells [1,2]. p53 transactivation
activity is stimulated by a variety of cellular insults, including
infection, DNA damage, and oxidative damage. Studies
have linked p53’s transactivation activity to acetylation of
both p53 itself [3–5] as well as histones, including those
within p53 target promoters [6–8]. Acetylation of both p53
and histones appears to occur through recruitment of his-
tone acetyltransferases (HATs), which include p300, CREB-
binding protein (CBP), and p300/CBP–associated factor
(PCAF) [4,9,10]. In addition, all three coactivators acetylate
p53 in response to DNA damage, thus increasing p53’s se-
quence-specific DNA-binding ability at target promoters [4,5].
The significance of PCAF in p53’s control of cell growth is
also suggested by studies investigating the early region 1 (E1)
of the adenovirus genome. The adenovirus genome produces
E1A RNA, which is spliced into 12S and 13S transcripts to
produce proteins of 243 and 289 amino acids, respectively.
The E1B region produces two transcripts with overlapping
reading frames: one for a 19-kDa protein that inhibits apoptosis
and the other for a larger 55-kDa protein. Several studies have
reported that the larger of the E1B proteins functions to inhibit
p53 acetylation by PCAF, whereas the E1A protein inhibits
nucleosomal acetylation by PCAF [6,10,11]. The fact that the
adenoviral E1 proteins specifically target PCAF’s interactions
with p53 and its coactivators to transform cells indicates
the importance of PCAF in p53’s function.
In a prior study, we used cDNA microarrays to investigate
the response of breast epithelial cell lines to adenovirally
transduced wild-type p53 [8]. Eleven breast epithelial cell lines,
nine p53 mutants and two wild type for p53, were compared to
untreated MCF10A cells following 24 hours of either adenoviral
infection with empty vector or infection with adenoviral vector
expressing wild-type p53. Multidimensional scaling identified a
cluster of eight cell lines that were p53-responsive. The re-
sponsive cell lines were then used to identify genes induced by
adenoviral transduction of wild-type p53, but not adenoviral
infection with empty vector or no treatment. Selection of
responsive genes was by similarity (Pearson’s correlation
coefficient of 0.99) of their expression pattern to that of a
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previously identified p53-inducible gene quinone oxidoreduc-
tase (PIG3) [12]. The responsive genes selected in this
manner included PCAF, and led to the hypothesis that PCAF
was a p53 target gene.
Two cells lines, UACC-1179 and BT-549, which had
induced PCAF following adenoviral transduction of wild-type
p53 as measured by microarray, were selected for further
study. To test PCAF induction further in UACC-1179 and
BT-549, the time course of both PCAF and p53 induction
following adenoviral transduction of wild-type p53 was de-
termined using real-time reverse transcription–polymerase
chain reaction (RT–PCR). Direct activation of PCAF expres-
sion by p53 was investigated by measuring p53 binding to
the PCAF promoter in the area of a p53 consensus-binding
site using chromatin immunoprecipitation (ChIP). Further
experiments using MCF10A cells, which are wild type for
p53, measured the dose and time dependence of PCAF
induction following activation of endogenous p53 activity by
doxorubicin. To further confirm the role of p53 in PCAF
induction, siRNA directed against p53 mRNA was used to
reduce activated p53 levels in MCF10A cells prior to doxo-
rubicin treatment. A subsequent decrease in PCAF induction
as a result of pretreatment with siRNA against p53 mRNA
was demonstrated. Taken together, the results support
PCAF as a p53 target gene.
Materials and Methods
Cell Culture
TheMCF10A, MDA-MB-435, MDA-MB-231, MDA-MB-157,
MDA-MB-468, BT-549, and Hs578T breast cancer cells
were obtained from the American Type Culture Collection
(Rockville, MD). The remaining cell lines were early pas-
sage sporadic breast cancer cell lines developed and main-
tained at the Arizona Cancer Center Cell Culture Shared
Service (Tucson, AZ).UACC-1179 andUACC-2087 cell lines
were derived from pleural effusions, whereas UACC-893
was derived from a primary tumor [13–15]. MDA-MB-435
and MDA-MB-231 were maintained in RPMI 1640 containing
5% fetal bovine serum supplemented with 50 mg/ml penicillin/
streptomycin. MDA-MB-468, BT-549, and Hs578T were
maintained in RPMI 1640 containing 10% fetal bovine serum
supplemented with 50 mg/ml penicillin/streptomycin. MDA-
MB-453, MDA-MB-157, UACC-1179, and UACC-2087 were
maintained in M15 containing 5% fetal bovine serum supple-
mented with 50 mg/ml penicillin/streptomycin. MCF10A was
maintained in mammary epithelial growth media (Cell Appli-
cations, Inc., San Diego, CA).
Adenoviral Infection
Recombinant adenovirus serotype 5 containing wild-type
p53 with a green fluorescent protein (GFP) detection marker
(p53) or with GFP alone (empty vector) were a kind gift of
Bert Vogelstein [16] and were propagated at the Gene
Transfer Vector Core, University of Iowa (Iowa City, IA).
Breast cancer cell lines were grown, counted, and then
infected with 200 pfu/cell of either GFP adenovirus 5 or
p53/GFP adenovirus 5. Infection efficiency was monitored
by scoring cells for GFP production using flow cytometry and
fluorescence microscopy; each virus resulted in >95% infec-
tion efficiency.
Microarray Analysis
The probe, target, and microarray fabrication were
performed as previously described [17]. Briefly, 5184 se-
quence-validated IMAGE consortium bacterial clones were
purchased from Research Genetics (Huntsville, AL; catalog
no. gf200). Probes were produced by PCR amplification of
the cDNA inserts directly from bacterial cultures. Primers
and unincorporated nucleotides were removed using a 96-
well PCR clean-up kit from Qiagen (Valencia, CA). After
quantitation, the purified PCR products were dried and
resuspended in 10 ml of 2 SSC and printed onto amino-
alkylsilane-modified glass slides (catalog no. S4651; Sigma,
St. Louis, MO) using four quill-type pins (catalog no.
SMP4; Telechem International, San Jose, CA) mounted
onto an OmniGrid robot (GeneMachines, San Carlos, CA).
A list of the clones on the array is available upon request.
After printing, the slides were fixed, washed, and stored in
the dark at room temperature and <40% humidity until use.
Fluorescent cDNA was made from reverse transcription
of 40 mg of total RNA in the presence of 50 mM Cy5-dCTP
or Cy3-dCTP (Amersham Pharmacia Biotechnology,
Piscataway, NJ) in a 25-ml volume containing the following:
500 ng of oligo dT [12–18]; 1 Superscript Buffer; 400 U of
Superscript II; 3.3 U of RNAse inhibitor (all from Gibco BRL,
Grand Island, NY); 400 mM each of dGTP, dATP, and dTTP;
100 mM dCTP; and 10 mM dithiothreitol. The cDNA target
was purified, lyophilized to dryness, resuspended in 10 ml of
hybridization buffer (2 SSC, 0.1% sodium dodecyl sulfate
[SDS], 100 ng/ml CotI DNA, 100 ng/ml oligo dA), denatured by
boiling for 2.5 minutes, and hybridized to a microarray
overnight at 62jC for 18 hours. Following hybridization,
slides were washed and scanned for Cy3 and Cy5 fluores-
cence using an Axon GenePix 4000 microarray reader (Axon
Instruments, Foster City, CA) and quantitated using GenePix
software. Results were loaded into GeneSpring (Silicon
Genetics, Redwood City, CA) and normalized using Lowess
intensity-dependent normalization, and PCAF expression
ratios for all 11 cell lines were examined.
Real-Time RT–PCR Analysis
UACC-1179 and BT-549 cells were infected with recom-
binant adenovirus serotype 5 containing GFP detection
marker only (empty vector) or wild-type p53 and GFP detec-
tion marker (p53). RNA was isolated at 0, 12, 18, 24, and
36 hours followed by real-time RT–PCR. Reverse transcrip-
tion used TaqMan Reverse Transcription Reagents (Roche
Molecular Systems, Branchburg, NJ) and 200 ng of total
RNA in a 50-ml reaction. Reverse transcription was primed
with random hexamers and incubated at 25jC for 10 minutes
followed by 48jC for 30 minutes, 95jC for 5 minutes, and a
chill at 4jC. Each PCR reaction consisted of 3.75 ml of
cDNA added to 12.5 ml of TaqMan Universal PCR Master
Mix (Roche Molecular Systems), 1.25 ml of gene-specific
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primer/probe mix (Assays-by-Design; Applied Biosystems,
Foster City, CA) and 7.5 ml of PCR water. PCR conditions
were: 95jC for 10 minutes, followed by 40 cycles of 95jC
for 15 seconds, alternating with 60jC for 1 minute using an
Applied Biosystems 7000 SDS and Applied Biosystems’
Assays On Demand primers specific to PCAF (assay ID
Hs00187332 m1) and GAPDH (assay ID Hs99999905 m1).
PCAF-specific product was normalized to GAPDH and
quantitated using the comparative (DDC t) C t method as
described in the ABI Prism 7000 sequence detection system
user guide. PCAF and p53 expression values were averaged
across three independent experiments in each cell line and
standard error was calculated for graphing.
ChIP/Real-Time PCR Analysis
The ChIP assay for p53 bound to target promoters was
performed as described previously [8]. Briefly, intact liv-
ing cells were treated with 1% formaldehyde to form
DNA–protein cross-links. Cells were then collected by cen-
trifugation and resuspended in an SDS lysis buffer. DNA–
protein complexes were sonicated to approximately 700 bp
as determined by gel electrophoresis. One tenth of the
sample was set aside for input control and the remaining
sample was precleared with A/G PLUS Agarose (Santa Cruz
Biotechnology, Santa Cruz, CA). Following preclearing, the
sample was split in half and one portion was incubated with
30 ml of anti–p53 antibody conjugated to agarose beads
(clone DO1; Oncogene Research Products, Boston, MA) or
30 ml of protein A/G PLUS agarose. The other half of the
sample was mock-incubated by leaving out the anti–p53
antibody and provided a no-antibody control for nonspecific
protein–DNA binding. After incubation, beads were washed
and chromatin–antibody complexes were eluted. DNA–
protein cross-links in all samples, including the input DNA
control, were reversed and DNA-purified for amplification.
Real-time PCR was used to analyze chromatin-immuno-
precipitated DNA and input control DNA, using an ABI Prism
7000 sequence detection system (Applied Biosystems) de-
tector. Real-time PCR was carried out in triplicate on 5 ng of
DNA at 95jC for 10 minutes, followed by 40 cycles of 95jC
for 15 seconds, 60jC for 1 minute, and 72jC for 1 minute.
PCAF promoter-specific primers (Assays by Design; Applied
Biosystems) were used at a final concentration of 500 nM
for both forward and reverse primers (forward primer:
GCACAATTTTGAAAACTACGTAACG; reverse primer:
ATGCAGTGGAAAAAGTTTGAATACAA; TaqMan 6-FAM
dye-labeled probe: CCAGAAACGAATCCT). Primers were
designed to probe the f500-bp 5V region of the PCAF
transcription start site; the amplicon was designed to overlap
specifically with a region rich in p53 consensus-binding sites
(5V-PuPuPuC(A/T)(T/A)GPyPyPy-3V separated by 0–13 bp
[18]). The presence of a single PCR product of correct size
was confirmed by agarose gel electrophoresis. Quantitation
was determined by applying the comparative C t method.
Briefly, fold enrichment was calculated by subtracting the C t
value of the ChIP DNA from the C t value of the input DNA
fraction and by using this value as the power to which 2 is
raised (i.e., 2C t(Input)C t(ChIP) ).
Activation of p53 by Doxorubicin and Knock Down with
siRNA
MCF10A cells were mock-transfected for 6 hours and
treated with doxorubicin, or transfected with a pool of five
siRNAs (SMARTPool siRNA; Dharmacon RNA Technolo-
gies, Lafayette, CO) directed against p53 RNA for 6 hours
followed by treatment with doxorubicin (Sigma) in six-well
plates. RNA was isolated using an RNeasy Kit (Qiagen) and
analyzed for PCAF expression by reverse transcription cou-
pled with real-time PCR on an Applied Biosystems 7000
sequence detection system using the primers and probe
described above. For the doxorubicin, dose-response RNA
was isolated 18 hours after 0, 0.2, 0.5, 0.75, and 1 mM
doxorubicin treatment; for the time course, RNA was isolated
at 0, 12, 18, 24, 36, and 48 hours after a doxorubicin dose of
0.5 mM. PCAF PCR product was normalized to GAPDH and
quantitated using the comparative Ct method as described
above. PCAF expression was expressed relative to control
(0 mMdoxorubicin in the dose response and time 0 in the time
course). The dose-response experiment was averaged
across three independent experiments, and graphed along
with the standard error. The time course experiment was run
twice with similar results.
Western Blot Analysis
Total cell lysate was separated on a 10% SDS-PAGE gel
and transferred to PVDF membrane by standard methods.
An anti–p53 mouse monoclonal antibody (clone DO1; On-
cogene Research Products) diluted 1:1000 followed by a
1:10,000 dilution of goat anti–mouse HRP was used to
detect p53. The b-actin used as a loading control was
detected with a 1:2000 dilution of b-actin antibody (clone
AC-40; Sigma) followed by a 1:10,000 dilution of goat anti–
mouse horseradish peroxidase. The horseradish peroxi-
dase–conjugated antibodies were visualized by exposure
of the blot to enhanced chemiluminescence (ECL) staining
(Amersham Pharmacia Biotechnology). The experiment was
performed independently three times with similar results.
Densitometry was used to quantitate b-actin and p53 bands.
Each p53 band was normalized to the b-actin band in the
same lane, and then normalized to the untreated control to
calculate the fold induction shown.
Results
Table 1 shows the breast cell lines studied, PCAF in-
duction following adenoviral transduction of empty vector or
wild-type p53, p53 status/type of mutation, and p53 respon-
siveness. Each of the 11 cell lines was infected with an
empty adenoviral vector or a vector expressing wild-type
p53 and compared in a two-color hybridization to untreated
MCF10A cells. The ratio of PCAF expression relative to
MCF10A following the two treatments is shown in the sec-
ond and third columns. To express PCAF induction within
each cell line relative to treatment rather than MCF10A, the
p53-infected ratio was divided by the empty vector ratio. The
resulting PCAF induction ranged from 1.2 to 9.5 and is
shown as (p53/empty vector). The average increase in
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PCAF expression in wild-type p53-infected cells over empty
vector-infected cells was 3.5.
The UACC-1179 and BT-549 cell lines, which were both
p53-mutant and responsive to transduced wild-type p53,
were selected to further study PCAF induction by p53. First,
the microarray results were expanded into a time course of
p53 and PCAF induction following infection with wild-type
p53 using real-time RT–PCR (Figure 1, A and B). The results
confirmed PCAF induction following wild-type p53 infection
and showed that induction of PCAF mRNA was time-depen-
dent, whereas infection with empty adenoviral vector had no
affect. In UACC-1179 cells at 36 hours, the average induc-
tion across three independent replicates was 4.2, whereas
the BT-549 cells were more responsive to p53 infection
with an average induction of 5.9 in three independent infec-
tions. At 24 hours, the time used in the microarray experi-
ments, the measured induction in UACC-1179 cells was 1.6,
compared to 3.4 when measured by microarray. In BT-549
cells, PCAF induction measured by real-time RT–PCR was
4.5, compared to 3.7-fold when measured by microarray.
Because p53 activates transcription through binding to
target promoters, the PCAF promoter was analyzed for
tandem p53 consensus-binding sites. The PCAF promoter
was found to contain multiple p53 consensus-binding sites;
however, primers and probe were designed to query two
regions at 400 and 580 bp from transcription start be-
cause they contained multiple overlapping potential p53-
binding sites (Figure 2A). To test if p53 bound directly to the
PCAF promoter, UACC-1179 and BT-549 cells infected with
wild-type p53 were subjected to ChIP followed by real-time
PCR amplification of the PCAF promoter. Intact wild-type
p53-infected and control cells were treated with formalde-
hyde to cross-link genomic DNA to any bound proteins.
The genomic DNA was isolated, sonicated into approxi-
mately 700-bp fragments, and a portion was immunopreci-
pitated with antibody to wild-type p53. Subsequent PCR
amplification using primers specific to the PCAF promoter
allowed the relative amount of p53-immunoprecipitated
PCAF promoter in infected and control cells to be compared.
The results in Figure 2, B and C show representative
amplification plots from UACC-1179 and BT-549 cells. Com-
parison of the PCAF amplification curves from p53-infected
and untreated control cells without immunoprecipitation
revealed nearly identical amounts of PCAF promoter DNA
in the samples (compare open squares to open circles). This
result showed that equal amounts of input genomic DNA
result in equal amounts of PCAF PCR product in the absence
of enrichment using p53 antibody. In contrast, when the
genomic DNA was immunoprecipitated with p53 antibody
prior to amplification, the PCAF promoter amplified earlier
from p53-infected cells rather than from untreated cells
(compare closed squares to closed circles). Across three
independent experiments, the average increase in p53 bind-
ing to the PCAF promoter in p53-infected cells was 8 ± 4 in
UACC-1179 cells and 4 ± 2 in BT-549 cells compared to
control. A negative control was done by performing the ChIP
assay with a mock immunoprecipitation (no anti–p53 anti-
body); no significant product was amplified from these sam-
ples and therefore the amplification curves are not plotted in
Figure 2, B and C. These results demonstrate that the wild-
type p53 expressed from the adenoviral vector bound to the
PCAF promoter in vivo, and support direct p53 transactiva-
tion of the PCAF promoter.
To verify the connection between wild-type p53 activity
and PCAF expression, the endogenous wild-type p53 within
MCF10A breast epithelial cells was activated and PCAF
induction was measured using real-time PCR. Doxorubicin,
a DNA-damaging agent, was used to stimulate p53 activity
at concentrations of 0.2 to 0.75 mM. To show that PCAF
induction following activation of p53 was, in fact, p53-depen-
dent, some cells were pretreated with siRNA directed against
p53 in order to block the accumulation of activated p53
following doxorubicin treatment. Figure 3A shows that after
18 hours after doxorubicin treatment, PCAF expression was
induced in a dose-dependent manner, with the maximal
induction at 0.75 mM (closed diamonds). To demonstrate
Table 1. Breast Cell Lines Studied, PCAF Induction Following Adenoviral Transduction of Empty Vector or Wild-Type p53, p53 Status/Type of Mutation, and
p53 Responsiveness.
Cell Line (Empty Vector/MCF10A) (p53-Transduced/MCF10A) (p53/Empty Vector) p53 Mutation p53 Responsive?
MCF10A 0.6 1.5 2.7 Wild type Yes
UACC-1179 0.7 2.5 3.4 R213X Yes
UACC-2087 0.4 1.1 2.9 V216M No
UACC-893 0.4 1.2 2.9 Wild type Yes
BT-549 1.1 4.0 3.7 R249S Yes
HS-578T 0.5 1.0 2.2 V157T No
MDA-MB-435 2.7 3.2 1.2 G226E No
MDA-MB-231 0.8 2.7 3.3 R280K Yes
MDA-MB-157 0.7 3.2 4.7 Del codons 2–4 Yes
MDA-MB-468 0.5 1.3 2.4 R273H Yes
MDA-MB-453 0.6 5.4 9.5 Del codons 368 Yes
Average 0.8 2.5 3.5
PCAF expression was measured by cDNA microarray. Ratios in the first two columns show PCAF expression in the cell lines relative to untreated MCF10A cells
following adenoviral transduction with empty vector (empty vector/MCF10A) or wild-type p53 (p53-transduced/MCF10A). To express PCAF induction within each
cell line relative to treatment rather than MCF10A, the MCF10A reference was determined by dividing the (p53-transduced/MCF10A) ratio by the (empty
vector/MCF10A) ratio. The resulting PCAF induction is shown as (p53/empty vector). The p53 status of each cell line was determined from the literature
(http://p53.curie.fr) or as described previously [8]. Responsiveness to p53 was determined by multidimensional scaling as described previously [8].
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that the induction of PCAF was p53-dependent, MCF10A
cells were treated with a pool of five siRNAs targeted against
p53 RNA for 6 hours prior to the 18 hours of doxorubicin
treatment. Compared to the mock-transfected cells, cells
transfected with siRNAs against p53 RNA induced less
PCAF expression at similar doses of doxorubicin (Figure 3A,
open squares).
To confirm that the reduced PCAF induction in siRNA-
treated cells was due to a loss of active p53, a Western blot
analysis was performed to compare p53 protein levels
following doxorubicin treatment or siRNA transfection and
doxorubicin treatment. Figure 3B shows that the amount of
p53 protein increased with doxorubicin dose (top panel ),
whereas pretreatment with siRNAs directed against p53
mRNA decreased p53 protein accumulation (bottom panel ).
For example, when normalized to the b-actin control, p53
protein at the 0.75 mM doxorubicin dose was 10-fold in-
creased over control, but in siRNA-pretreated cells, p53
protein was induced only two-fold over control. The lower
p53 protein accumulation in siRNA-pretreated cells after
doxorubicin treatment correlates with the reduced PCAF
induction observed in Figure 3A.
Figure 2. (A) Diagram of the PCAF promoter region analyzed for p53 binding.
The bent arrow represents the transcription start site, whereas the filled
rectangle shows the first exon. The vertical arrows represent tandem p53
consensus-binding sites with greater than 80% match to the published
consensus sequence. The open rectangles show the location of the primers
used to amplify the PCAF promoter, and striped rectangle shows the position
of the probe. The numbers indicate nucleotide position relative to tran-
scription start. (B and C) p53 binds the PCAF promoter in vivo in wild-type
p53– infected breast cancer cells. p53 binding to the PCAF promoter was
measured in UACC-1179 and BT-549 after 24 hours of no treatment or after
24 hours of infection with wild-type p53 using ChIP coupled to real-time PCR
analysis. Chromatin was immunoprecipitated using a p53 antibody (clone
DO1) and PCAF promoter-specific real-time PCR was performed on input
control DNA and DNA from the immunoprecipitated chromatin. The threshold
bar for Ct determination was set within the linear range of PCR amplification
and fold enrichment of p53 binding was determined by the comparative Ct
method. The experiment was performed independently three times in each
cell line with similar results; representative real-time PCR graphs are shown.
Average fold enrichment of p53 binding was 8 ± 4 in UACC-1179 cells and
4 ± 2 in BT-549 cells compared to control.
Figure 1. (A and B) p53 induces PCAF expression in p53 mutant breast
cancer cells infected with wild-type p53. RNA from UACC-1179 and BT-549
cells was collected 6, 12, 18, 24, and 36 hours after infection with wild-type
p53 and used to quantitate PCAF and p53 expression relative to time zero
using real-time RT–PCR. Closed circles and squares represent p53 and
PCAF expression in wild-type p53– infected UACC-1179 and BT-549 cells,
whereas open circles and squares represent p53 and PCAF expression in
empty vector– infected UACC-1179 and BT-549 cells. Each cell line was
independently infected in triplicate; average expression is shown with one
standard error (SE).
PCAF is a p53 Target Gene Watts et al. 191
Neoplasia . Vol. 6, No. 3, 2004
Lastly, in support of direct p53 activation of the PCAF
promoter, a time course of PCAF induction was performed
following treatment of MCF10A cells with 0.5 mMdoxorubicin.
This was the dose of doxorubicin shown to cause an eight-
fold accumulation of p53 protein after 18 hours in Figure 3B;
if PCAFwas a direct target of p53 transactivation, then PCAF
induction should occur soon after p53 accumulation. As seen
in Figure 3C, PCAF mRNA was increased nearly two-fold at
12 hours following doxorubicin treatment and continued to
rise up to 18 hours at which point PCAF mRNA declined
slowly. This result confirms that PCAF mRNA increased
rapidly following stimulation of p53 activity by doxorubicin
and, along with the ChIP results, suggests that PCAF is a
direct target of p53.
Discussion
The purpose of the studies presented here was to investigate
the unexpected finding that PCAF was induced in breast
cells transduced with wild-type p53. This observation was
first made from the microarray data presented in Table 1. By
calculating the PCAF induction relative to the empty vector
control in Table 1, we insured that the calculated increase in
PCAF expression was p53-specific, and not a result of the
adenoviral infection itself. It is important to note that the p53
responsiveness listed in Table 1 was determined by multi-
dimensional scaling based on the response of many genes,
not PCAF alone. This distinction becomes important when
considering that the three cell lines that were categorized as
unresponsive to p53, of which two still induced PCAF. These
three cell lines did not show a strong-enough response
across the f5000 genes queried to be grouped with the
cluster of responsive cell lines and thus are labeled unre-
sponsive. Most importantly, this result should not be inter-
preted as indicating that PCAFwas induced independently of
p53 expression. Instead, PCAF was induced specifically by
expression of wild-type p53 even when many other genes
were not; this observation provides further evidence that
PCAF was a direct target of p53. Interestingly, the lone cell
line, MDA-MB-435, that did not induce PCAF may actually
be a melanoma [19,20].
The induction of PCAF by p53 was confirmed and ex-
panded by a time course study in which PCAF and p53
expression in UACC-1179 and BT-549 cells was shown to
increase with time following infection with wild-type p53.
Although both cell lines induced PCAF, BT-549 showed a
more robust response than UACC-1179 despite having a
smaller induction of p53 mRNA. These results likely reflect
differences in the efficiency with which the adenoviral
vector can express p53 mRNA in the two cell lines. Having
Figure 3. (A) Activation of endogenous wild-type p53 in MCF10A cells using
doxorubicin induces PCAF expression, whereas loss of p53 prior to
doxorubicin treatment reduces PCAF induction. MCF10A cells were mock-
transfected for 6 hours and treated with doxorubicin or transfected with a pool
of five siRNAs directed against p53 RNA for 6 hours followed by treatment
with doxorubicin. At 24 hours, RNA was harvested and PCAF expression was
quantitated using real-time RT–PCR. The average of three independent
experiments is shown ±1 SE. (B) Western blot analysis showing accumu-
lation of p53 protein following treatment with doxorubicin, or doxorubicin and
siRNAs directed against p53. The top panel shows p53 accumulation
following doxorubicin treatment; the bottom panel shows the same after
pretreatment with siRNAs against p53. Bands were quantitated using
densitometry and normalized first to the -actin loading control and then to
the untreated control (left lane of each panel) to calculate the increase over
control shown below each western. (C) Representative time course of PCAF
induction following doxorubicin treatment of MCF10A cells. Cells were treated
with 0.5 M doxorubicin and RNA were harvested at the times indicated.
PCAF mRNA was quantitated using real-time RT–PCR, normalized to
GAPDH, and expressed relative to time zero.
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confirmed the microarray results, ChIP using p53 antibody
and real-time PCR amplification of the PCAF promoter
showed that the induction of PCAF expression was associ-
ated with increased p53 binding to the PCAF promoter
in vivo. The exact sequence to which wild-type p53 bound
in the PCAF promoter was not identified by the ChIP assay;
however, the primers and probe used to amplify the PCAF
promoter likely recognize one of the p53-binding sites locat-
ed in the 500-bp surrounding the primer probe upstream of
the transcription start site. A search for tandem p53 consen-
sus-binding sites in the 2-kb upstream of the PCAF tran-
scription start site revealed two regions, at approximately
400 and 580, that contained multiple overlapping tandem
consensus-binding sites for p53. The primers and probe
used to amplify the PCAF promoter were designed to overlap
the 580 region (Figure 2A), but would likely have detected
p53 binding to the 400 region as well. Regardless of
whether p53 was binding to one or both of these regions,
the ChIP assay showed conclusively that in vivo p53 binding
to the PCAF promoter increased when cells were infected
with wild-type p53.
Recognizing that PCAF induction may have resulted from
artificially high expression of wild-type p53 by the adenoviral
vector, we switched to a more physiologically representative
model for further studies. The model consisted of wild-type
p53-expressing MCF10A cells in which p53 activity was
induced by treating the cells with doxorubicin. PCAF induc-
tion by endogenous p53 in doxorubicin-treated MCF10A
cells was measured using real-time RT–PCR. The results
showed that PCAF induction increased with doxorubicin
dose (Figure 3A), whereas a Western blot analysis con-
firmed concomitant accumulation of p53 protein (Figure 3B,
top panel ). Additionally, siRNA knockdown of p53 prior to
doxorubicin treatment showed that reducing activated p53
protein (Figure 3B, lower panel ) resulted in the reduction of
PCAF expression (Figure 3A). In addition to demonstrating
that PCAF induction was p53-dependent, these results
showing induction of PCAF by endogenous p53 confirmed
that the results seen with adenoviral transduction were not
an artifact of overexpression of wild-type p53. Lastly, we
performed a time course of PCAF induction in the MCF10A
doxorubicin model, which showed that PCAFwas induced as
early as 12 hours following doxorubicin treatment and sup-
ported the results from the ChIP analysis suggesting that
PCAF is a direct p53 target.
Stimulation of p53 by cellular insult, such as treatment
with the DNA-damaging agent doxorubicin, leads to trans-
activation of gene expression by p53 and its coactivators
such as PCAF. Because PCAF can acetylate p53 and
histones, the results presented here suggest that a type of
signal amplification may be possible. It is possible that the
induced PCAF expression could lead to increased PCAF
recruitment at p53-bound target promoters where PCAF
could acetylate p53 and/or histones, thus increasing p53’s
transactivation activity. Such a series of events is suggested
by recent studies in which p53 binding and acetylation
appear to increase the recruitment of HATs to p53 target
promoters with a subsequent increase in histone acetyla-
tion and transcription [8,21,22]. Additionally, PCAF has
recently been shown to have a substrate preference for
histone H3 N-terminal residues and histone H3 acetylation
in two tumor-suppressor gene promoters increased following
expression of p53 [7]. Finally, MDM2 was recently shown to
inhibit PCAF acetylation of p53 [23]. Taken together with the
results reported here, it appears possible that transactivation
of p53 target genes may be controlled by a balance between
the competing effects of PCAF and MDM2 in their interac-
tions with p53 at the gene and protein levels.
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